A letterfrom ourgeneralmanager

We believe that our commitment to “patients first” and to doing this through a very personal, partnership-based approach is what sets us apart as a very different type of rare disease company. In this context, I am immensely proud of the work we do as a company to support the NHS long-term plan and ambition for prevention, empowering people to control their own health, and improving the quality of patient care and health outcomes through the fostering of strong relationships with healthcare professionals, patient groups, regulators, payers, policymakers, and government bodies. With our approach of collaboration, listening, learning, and sharing, we have also made strides to work with regulators and HTA bodies to bring our medicines to patients as soon as possible. We are proud of the difference this is making.

While much has been achieved, I am looking forward to what is yet to come. This is an exciting time for BioCryst, as our footprint and impact grow in the UK, Europe, and beyond, making us even more effective locally while at the same time providing greater opportunities for everyone—our people and the patients we serve.

If you would like to learn more about our science and medicine or how we work in the UK, I would encourage you to get in contact.

Sincerely,

Luke Robinson
General Manager, UK, Ireland & Nordics